McClarren Financial Advisors Inc. Takes $124,000 Position in Stryker Co. (NYSE:SYK)

McClarren Financial Advisors Inc. purchased a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 347 shares of the medical technology company’s stock, valued at approximately $124,000.

Other hedge funds have also added to or reduced their stakes in the company. Opal Wealth Advisors LLC boosted its holdings in shares of Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after purchasing an additional 28 shares in the last quarter. Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the last quarter. Capital & Planning LLC boosted its stake in Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after buying an additional 29 shares in the last quarter. Concord Wealth Partners grew its position in Stryker by 2.2% in the fourth quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 30 shares during the last quarter. Finally, Avestar Capital LLC raised its stake in Stryker by 1.1% during the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after acquiring an additional 31 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 1.3 %

NYSE:SYK opened at $385.49 on Thursday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm’s fifty day moving average is $377.27 and its 200-day moving average is $366.01. The firm has a market cap of $146.96 billion, a P/E ratio of 49.68, a P/E/G ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s payout ratio is currently 43.30%.

Analysts Set New Price Targets

Several brokerages recently issued reports on SYK. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Piper Sandler reiterated an “overweight” rating and issued a $420.00 price target (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.